Division of Cardiology, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA; Departments of Medicine and Pediatrics, Tufts University School of Medicine, Boston, Massachusetts, USA.
Can J Cardiol. 2020 Sep;36(9):1545-1549. doi: 10.1016/j.cjca.2020.05.035. Epub 2020 Jun 3.
The pediatric lipid screening and treatment practices, attitudes, and perceived barriers of Canadian pediatricians are not known. We sought to evaluate this in a survey of pediatricians through the Canadian Pediatric Surveillance Program (CPSP) in March 2019. The survey included an assessment of lipid screening of 9- to 11-year-old youth and a hypothetical case of persistent severe dyslipidemia to ascertain management practices. There were 759 respondents (28% response rate, 759 of 2742), of whom 236 provided outpatient primary care to 9- to 11-year-old youth as part of their routine clinical practice. Among primary care-providing pediatricians, universal lipid screening of healthy 9- to 11-year-old youth most or all of the time was reported by 3% (8 of 230). Reported screening practices most or all of the time were more common for youth with risk factors such as overweight and obesity (54%, 127 of 235) and a family history of premature cardiovascular disease (39%, 85 of 217). Most respondents would refer a child with severe persistent dyslipidemia to dieticians (69%, 152 of 220) and a lipid specialist (64%, 144 of 220) most or all of the time, whereas 7% (16 of 220) would start statin therapy themselves. A lack of Canadian pediatric lipid guidelines was reported as a major barrier for 49% (114 of 233) and minor barrier for 40% (93 of 213). The rate of routine lipid screening of healthy 9- to 11-year-old youth among Canadian primary care-providing pediatricians is low and at odds with current US guidelines. This discrepancy may be due at least in part to a lack of Canadian guidelines on pediatric dyslipidemia, the development of which may address certain perceived barriers and influence future attitudes.
加拿大儿科医生的小儿血脂筛查和治疗实践、态度以及感知障碍尚不清楚。我们通过 2019 年 3 月的加拿大儿科监测计划(CPSP)对儿科医生进行了调查,旨在评估这一点。该调查包括对 9 至 11 岁青少年进行血脂筛查的评估,以及一个持续性严重血脂异常的假设病例,以确定管理实践。共有 759 名受访者(28%的回复率,2742 名中的 759 名),其中 236 名受访者作为其常规临床实践的一部分,为 9 至 11 岁的青少年提供门诊初级保健。在提供初级保健的儿科医生中,3%(230 人中的 8 人)报告称,他们会定期对健康的 9 至 11 岁青少年进行普遍血脂筛查。报告的筛查实践在大多数情况下或所有情况下更为常见,例如超重和肥胖(54%,235 人中的 127 人)和早发性心血管疾病家族史(39%,217 人中的 85 人)的青少年。大多数受访者会将严重持续性血脂异常的儿童转介给营养师(69%,220 人中的 152 人)和血脂专家(64%,220 人中的 144 人),大多数情况下或所有情况下,只有 7%(220 人中的 16 人)会自己开始他汀类药物治疗。49%(233 人中的 114 人)报告缺乏加拿大儿科脂质指南是一个主要障碍,40%(213 人中的 93 人)报告是一个次要障碍。加拿大提供初级保健的儿科医生对健康的 9 至 11 岁青少年进行常规血脂筛查的比例较低,这与目前的美国指南不一致。这种差异至少部分可能是由于缺乏加拿大儿科血脂异常指南,制定该指南可能会解决某些感知障碍,并影响未来的态度。
Pediatrics. 2001-7
Clin Pediatr (Phila). 2019-5
Paediatr Child Health. 2024-5-29
Medicina (Kaunas). 2024-9-29
Curr Atheroscler Rep. 2024-12
CJC Pediatr Congenit Heart Dis. 2023-6-20
CJC Pediatr Congenit Heart Dis. 2023-5-29
CMAJ Open. 2023-9-19
Circ Cardiovasc Qual Outcomes. 2023-9
Curr Atheroscler Rep. 2023-8